Developments in Medications for Hepatitis C
As one of the country's premiere hospitals for liver failure, University of Maryland doctors and researchers contribute to the advancement of new medications and treatment options for many liver diseases, including Hepatitis C. The FDA is approving new medications that will treat cirrhosis of the liver faster, easier and more effectively in patients with liver damage caused by chronic Hepatitis C.
Dr. William Hutson, University of Maryland transplant hepatologist, comments on what this new category of drugs means for patients with Hepatitis C.
Q: What are the differences between medications that already exist to treat Hepatitis C and new medications that are coming to market for patients?
A: We’re seeing a new category of drug. Previous drugs for Hep C were protease inhibitors, which means they attack a certain part of the Hep C virus. Now we’re seeing a new category of medicines called polymerase inhibitors, which means they attack a different part of the Hep C virus. Because they attack a different part of the virus, they’re more effective than any drug we’ve had so far. Even in patients who have cirrhosis of the liver, which has been difficult to treat, we’re seeing high cure rates. It’s amazing.
Continue reading the conversation or listen to a brief audio report on Hepatitis C from Dr. Hutson.